Renan Felipe Orellana-Walden

Dr. Renan Felipe Orellana-Walden

Departamento Ciencias Químicas y Biológicas, Universidad Bernardo O´Higgins, Santiago, Región Metropolitana, Chile
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Fertility and Sterility
Verified
Journal Article
Closed access
ODOlivier Donnez
Olivier Donnez
JDJacques Donnez
Jacques Donnez
Renan Felipe Orellana-WaldenRenan Felipe Orellana-Walden
Renan Felipe Orellana-Walden
MDMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

15 April 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Renan Felipe Orellana-WaldenRenan Felipe Orellana-Walden
Renan Felipe Orellana-Walden
SKSumie Kato
Sumie Kato
RERafaela Erices
Rafaela Erices
MBMaría Loreto Bravo
María Loreto Bravo
PGPamela Gonzalez
Pamela Gonzalez
GOGareth Owen
Gareth Owen
An increase in circulating platelets, or thrombocytosis, is recognized as an independent risk factor of bad prognosis and metastasis in patients with ovarian cancer; however the complex role of platelets in tumor progression has not been fully elucidated. Platelet activation has been associated with an epithelial to mesenchymal transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with hypercoagulable state and metastasis. The aim of this work was to determine the effect of platelet-cancer cell interaction on TF and “Metastasis Initiating Cell (MIC)” marker levels and migration in ovarian cancer cell lines and cancer cells isolated from the ascetic fluid of ovarian cancer patients. With informed patient consent, ascitic fluid isolated ovarian cancer cells, cell lines and ovarian cancer spheres were co-cultivated with human platelets. TF, EMT and stem cell marker levels were determined by Western blotting, flow cytometry and RT-PCR. Cancer cell migration was determined by Boyden chambers and the scratch assay. The co-culture of patient-derived ovarian cancer cells with platelets causes: 1) a phenotypic change in cancer cells, 2) chemoattraction and cancer cell migration, 3) induced MIC markers (EMT/stemness), 3) increased sphere formation and 4) increased TF protein levels and activity. We present the first evidence that platelets act as chemoattractants to cancer cells. Furthermore, platelets promote the formation of ovarian cancer spheres that express MIC markers and the metastatic protein TF. Our results suggest that platelet-cancer cell interaction plays a role in the formation of metastatic foci.

1 August 2015 in Fertility and Sterility
Verified
Journal Article
Closed access
ODOlivier Donnez
Olivier Donnez
Renan Felipe Orellana-WaldenRenan Felipe Orellana-Walden
Renan Felipe Orellana-Walden
OKOlivier Van Kerk
Olivier Van Kerk
JDJean-Paul Dehoux
Jean-Paul Dehoux
JDJacques Donnez
Jacques Donnez
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

1 April 2017 in Fertility and Sterility
Verified
Journal Article
Closed access
Renan Felipe Orellana-WaldenRenan Felipe Orellana-Walden
Renan Felipe Orellana-Walden
JGJavier García-Solares
Javier García-Solares
JDJacques Donnez
Jacques Donnez
OKOlivier van Kerk
Olivier van Kerk
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
ODOlivier Donnez
Olivier Donnez

30 November 2015 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
MCM.C. Chiti
M.C. Chiti
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Renan Felipe Orellana-WaldenRenan Felipe Orellana-Walden
Renan Felipe Orellana-Walden
MSM. Soares
M. Soares
FPF. Paulini
F. Paulini
CAC.A. Amorim
C.A. Amorim
Do primordial-primary versus secondary follicles embedded inside a fibrin matrix have different capabilities to survive and grow after isolation and transplantation? Mouse primordial-primary follicles showed a lower recovery rate than secondary follicles, but both were able to grow. Fresh isolated mouse follicles and ovarian stromal cells embedded in a fibrin matrix are capable of surviving and developing after short-term autografting. In vivo experimental model using 11 donor Naval Medical Research Institute (NMRI) mice and 11 recipient severe combined immunodeficiency (SCID) mice. Both ovaries from all NMRI mice were mechanically disrupted and primordial-primary and secondary follicles were isolated with ovarian stromal cells. They were then encapsulated in a fibrin matrix composed of 12.5 mg/ml of fibrinogen (F12.5) and 1 IU/ml of thrombin (T1) (F12.5/T1), and grafted to the inner part of the peritoneum of SCID mice for 2 and 7 days. This study was conducted at the Gynecology Research Unit, Université Catholique de Louvain. All materials were used to conduct histological (H-E staining) and immunohistochemical (Ki67, TUNEL) analyses. Although all grafted fibrin clots were recovered, the follicle recovery rate on day 2 was 16 and 40% for primordial-primary and secondary follicles respectively, while on day 7, it was 6 and 28%. The secondary group showed a significantly higher recovery rate than the primordial-primary group (23%, P-value <0.001). Follicles found in both groups were viable, as demonstrated by live/dead assays, and no difference was observed in the apoptosis rate between groups, as evidenced by TUNEL. Their growth to further stages was confirmed by Ki67 immunostaining. As demonstrated by our results, secondary follicles appear to be more likely to survive and develop than primordial-primary follicles in a fibrin matrix after both periods of grafting. These findings may also be attributed to the specific features of the fibrin matrix, which could benefit larger follicles, but not smaller follicles. This study is essential to understanding possible impairment caused by factors such as the isolation procedure or fibrin matrix composition to the survival and development of different follicle stages. It therefore provides the basis for further investigations with longer periods of grafting. This study was supported by grants from the Fonds National de la Recherche Scientifique de Belgique (grant Télévie No. 7.4578.14 and 7.4627.13, grant 5/4/150/5 awarded to Marie-Madeleine Dolmans), Fonds Spéciaux de Recherche, Fondation St Luc, the Foundation Against Cancer, and the Region Wallone (Convention N°6519-OVART) and donations from Mr Pietro Ferrero, Baron Frère and Viscount Philippe de Spoelberch. None of the authors have any competing interests to declare.

15 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
RERafaela Erices
Rafaela Erices
SCSofía Cubillos
Sofía Cubillos
RARaúl Aravena
Raúl Aravena
FSFelice Santoro
Felice Santoro
MMMonica Marquez
Monica Marquez
GOGareth Owen
Gareth Owen
Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression